A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adultsRobert P. McMahon, Juan Carlos Jaramillo, Nina Wressnigg et al.|Journal of Travel Medicine|2023Cited by 35